文献速递肿瘤 PET/CT核素与放射性配体治疗

以[64Cu]Cu/[177Lu]Lu-hu3F8对神经母细胞瘤进行GD2靶向诊疗一体化研究

GD2-targeted theranostics of neuroblastoma with [64Cu]Cu/[177Lu]Lu-hu3F8.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-12-20

本研究在神经母细胞瘤(NB)模型中评价抗GD2人源化单克隆抗体hu3F8的诊疗一体化潜力:经[64Cu]Cu-NOTA-hu3F8 PET显像评估GD2表达,并探索[177Lu]Lu-DOTA-hu3F8的放射免疫治疗效果。结果显示IMR32肿瘤模型在注射后72小时肿瘤摄取最高达23.73 ± 2.29%ID/g(n = 3),高剂量[177Lu]Lu-DOTA-hu3F8组(11.1MBq)抑瘤作用最强。作者认为该GD2靶向诊疗一体化方法可能有助于临床转化。

要点

  • IMR32细胞系显示hu3F8具有特异性结合能力。
  • [64Cu]Cu-NOTA-hu3F8在IMR32肿瘤模型注射后72小时肿瘤摄取最高达23.73 ± 2.29%ID/g(n = 3),显著优于其他组(P < 0.001)。
  • 高剂量[177Lu]Lu-DOTA-hu3F8组(11.1MBq)注射后30天标准化肿瘤体积约20.47 ± 6.32%,显著小于其他组(n = 5,P < 0.05)。

核心结论

  • 本研究证明64Cu-/177Lu标记的hu3F8可无创评估神经母细胞瘤肿瘤模型中的GD2表达,并有效抑制肿瘤生长。
  • [177Lu]Lu-DOTA-hu3F8的良好疗效可能有助于该GD2靶向诊疗一体化方法在GD2阳性肿瘤中的临床转化。

研究设计与样本

  • 本研究为在皮下神经母细胞瘤肿瘤模型中开展的临床前研究,采用流式细胞术、细胞免疫荧光和细胞摄取实验体外验证hu3F8与GD2的结合能力。
  • hu3F8分别与p-SCN-Bn-NOTA和p-SCN-Bn-DOTA偶联,用于64Cu和177Lu放射性标记。
  • 在皮下神经母细胞瘤肿瘤模型中使用[64Cu]Cu-NOTA-hu3F8进行PET显像、使用[177Lu]Lu-DOTA-hu3F8进行放射免疫治疗研究。

主要发现

  • IMR32细胞系显示hu3F8具有特异性结合能力。
  • [64Cu]Cu-NOTA-hu3F8在IMR32肿瘤模型中特异性蓄积,注射后72小时肿瘤摄取最高达23.73 ± 2.29%ID/g(n = 3),显著优于其他组(P < 0.001)。
  • 高剂量[177Lu]Lu-DOTA-hu3F8组(11.1MBq)抑瘤作用最强,注射后30天标准化肿瘤体积约20.47 ± 6.32%,显著小于其他组(n = 5,P < 0.05)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neuroblastoma (NB) is a malignant embryonic tumour with poor prognosis and high mortality rate. The antigen gisialoganglioside (GD2), which is highly expressed on the surface of NB cells, is an effective target for therapy. This study aims to evaluate the GD2 expression with [64Cu]Cu-NOTA-hu3F8 positron emission tomography (PET) imaging and explore the radioimmunotherapy (RIT) effect of [177Lu]Lu-DOTA-hu3F8 in NB tumour models. METHODS: The in vitro validation of the binding ability of anti-GD2 humanised monoclonal antibody (hu3F8) to GD2 was achieved via flow cytometry, cell immunofluorescence, and cell uptake test. Hu3F8 were conjugated with p-SCN-Bn-NOTA (NOTA) and p-SCN-Bn-DOTA (DOTA) for 64Cu- and 177Lu- radiolabelling. PET imaging and RIT studies were conducted using [64Cu]Cu-NOTA-hu3F8 and [177Lu]Lu-DOTA-hu3F8 in subcutaneous NB tumour models. RESULTS: The Institute for Medical Research-32 (IMR32) cell line exhibited a specific binding ability of hu3F8. PET imaging demonstrated a specific accumulation of [64Cu]Cu-NOTA-hu3F8 in IMR32 tumour models, with a maximum tumour uptake of 23.73 ± 2.29%ID/g (n = 3) at 72 h post-injection (p.i.), outperforming other groups significantly (P < 0.001). The high dose [177Lu]Lu-DOTA-hu3F8 group (11.1MBq) showed the most potent tumour suppression, with a standardised tumour volume of about 20.47 ± 6.32% at 30 days p.i., significantly smaller than other groups (n = 5, P < 0.05). CONCLUSION: This study demonstrated that 64Cu-/177Lu- labelled hu3F8 could noninvasively evaluate the GD2 expression and effectively inhibit tumour growth in NB tumour models. The excellent therapeutic efficacy of [177Lu]Lu-DOTA-hu3F8 may be helpful for the clinical translation of this GD2-targeted theranostics approach in GD2-positive tumours.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zheng L, Li C, Yang X, et al. GD2-targeted theranostics of neuroblastoma with [64Cu]Cu/[177Lu]Lu-hu3F8. Eur J Nucl Med Mol Imaging. 2024. PMID: 39702399. doi:10.1007/s00259-024-07033-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。